Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jun;293(6):724-752.
doi: 10.1111/joim.13627. Epub 2023 Mar 13.

Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis

Lindsay A Lo  1 , April Christiansen  2 , Lauren Eadie  3 , Justin C Strickland  4 , David D Kim  5 , Michael Boivin  6 , Alasdair M Barr  5   7 , Caroline A MacCallum  3
Affiliations
Free article
Meta-Analysis

Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis

Lindsay A Lo et al. J Intern Med. 2023 Jun.
Free article

Abstract

Background: Findings of liver enzyme elevations in recent cannabidiol studies have raised concerns over liver safety. This study aimed to determine the association between cannabidiol use, liver enzyme elevation, and drug-induced liver injury (DILI).

Methods: In this systematic review and meta-analysis, a search of EMBASE, CENTRAL, CINAHL, Clinicaltrials.gov, Medline, medRxiv, and Web of Science of records up to February 2022 was conducted. Clinical trials initiating daily cannabidiol treatment with serial liver enzyme measures were included. The proportion of liver enzyme elevations and DILI were independently extracted from published reports. Pooled proportions and probability meta-analyses were conducted.

Results: Cannabidiol use was associated with an increased probability of liver enzyme elevation (N = 12 trials, n = 1229; OR = 5.85 95% CI = 3.84-8.92, p < 0.001) and DILI (N = 12 trials, n = 1229; OR = 4.82 95% CI = 2.46-9.45, p < 0.001) compared to placebo controls. In participants taking cannabidiol (N = 28 trials, n = 1533), the pooled proportion of liver enzyme elevations was 0.074 (95% CI 0.0448-0.1212), and DILI was 0.0296 (95% CI 0.0136-0.0631). High-dose CBD (≥1000 mg/day or ≥20 mg/kg/day) and concomitant antiepileptic drug use were identified as risk factors. No cases were reported in adults using cannabidiol doses <300 mg/day. No cases of severe DILI were reported.

Conclusions: Cannabidiol-associated liver enzyme elevations and DILI meet the criteria of common adverse drug events. Clinicians are encouraged to screen for cannabidiol use and monitor liver function in patients at increased risk.

Keywords: CBD; adverse events; cannabidiol; drug-induced liver injury; liver.

PubMed Disclaimer

References

    1. Williamson EM, Liu X, Izzo AA. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. Br J Pharmacol. 2020;177(6):1227-40. https://doi.org/10.1111/bph.14943
    1. Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JAS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237-49. https://doi.org/10.2174/157488611798280924
    1. Bhamra SK, Desai A, Imani-Berendjestanki P, Horgan M. The emerging role of cannabidiol (CBD) products; a survey exploring the public's use and perceptions of CBD. Phytother Res. 2021;35(10):5734-40. https://doi.org/10.1002/ptr.7232
    1. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacol. 2020;45(11):1799-806. https://doi.org/10.1038/s41386-020-0667-2
    1. Manthey J. Cannabis use in Europe: current trends and public health concerns. Int J Drug Policy. 2019;68:93-6. https://doi.org/10.1016/j.drugpo.2019.03.006

LinkOut - more resources